GlassScriptPhysician profile
Azaret Villeda
NPI 1538824412
$2,595.42
in general payments reported to CMS, 2019-2025
36 companies · $620 in 2025
The $620 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $59.02 · 2022: $517 · 2023: $528 · 2024: $872 · 2025: $620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,020.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,019.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $359.75 | 2022-2025 | Jardiance, Mounjaro, Humulin |
| Novo Nordisk INC | $314.98 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Xeris Pharmaceuticals, INC. | $163.48 | 2022-2025 | Gvoke Hypopen |
| Amgen INC. | $148.23 | 2022-2025 | Tepezza, Evenity, Prolia |
| Beta Bionics, INC. | $134.75 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Abbvie INC. | $130.54 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.17 | 2021-2024 | Jardiance |
| Sequel Med Tech, LLC | $113.86 | 2025 | Twiist |
| Dexcom, INC. | $100.41 | 2023-2024 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $100.26 | 2023-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $99.77 | 2022-2024 | |
| Radius Health, INC. | $72.00 | 2023-2024 | Tymlos |
| Medtronic, INC. | $68.76 | 2023-2025 | Minimed 780g |
| Acella Pharmaceuticals, LLC | $55.69 | 2023-2024 | NP Thyroid 60 |
| Cequr Corporation | $51.83 | 2023-2024 | Cequr Simplicity |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $48.69 | 2022-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Amphastar Pharmaceuticals, INC. | $48.19 | 2024-2025 | |
| Amarin Pharma, INC. | $47.84 | 2022-2023 | |
| Recordati_rare_diseases_inc. | $43.28 | 2025 | Signifor Lar, Isturisa |
| Insulet Corporation | $37.38 | 2024-2025 | Omnipod |
| Antares Pharma, INC. | $35.90 | 2024-2025 | Xyosted |
| Intuity Medical INC | $35.36 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $33.62 | 2023-2024 | Farxiga, Lokelma |
| Amneal Pharmaceuticals LLC | $27.03 | 2022-2023 | Unithroid |
| Novartis Pharmaceuticals Corporation | $22.58 | 2022 | |
| Sanofi-Aventis U.S. LLC | $21.99 | 2022 | |
| Ascensia Diabetes Care US INC. | $21.36 | 2025 | |
| Alvogen INC | $20.14 | 2023 | Teriparatide |
| Halozyme INC | $19.55 | 2023 | |
| Azurity Pharmaceuticals, INC. | $16.60 | 2023 | Adthyza |
| Chiesi USA, INC. | $15.49 | 2024 | Mycapssa |
| Lifescan, INC. | $14.56 | 2023 | |
| Astellas Pharma US INC | $14.43 | 2024 | Veozah |
| Mannkind Corporation | $14.26 | 2021 | |
| Tolmar, INC. | $14.02 | 2023 | |
| Pfizer INC. | $13.67 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Azaret Villeda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.